IPILIMUMAB, NIVOLUMAB clinical trials
4 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic exploratory (Phase II)
EORTC-1525-LCG: Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym)
This study, named Nivothym, is looking at new treatments for a rare type of cancer called thymoma or thymic carcinoma. It's testing two medicines, ipilimumab and nivolumab, to see if they can help patients whose cancer has come back after chemotherapy. The main goal is to see if the cancer stays stable for at least six months.
For: type B3 thymoma and thymic carcinomaBelgium · Spain · Netherlands - AuthorisedTherapeutic exploratory (Phase II)
Tolerability and efficacy of treating locally advanced Resectable Oral Cancer with neoadjuvant INtratumoral anti-CTLA4 ImmunoTherapy combined with systemic anti-PD-1 (ROCinIT).
This clinical trial looks at a new way to treat mouth cancer before surgery. Doctors are testing whether injecting one immunotherapy drug directly into the tumour, alongside a second drug given through a vein, helps the immune system shrink the cancer safely before an operation takes place.
For: Oral cavity squamous cell carcinomaNetherlands - Active not recruitingPHASE2
SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
This study looks at combining a specific type of radiation, SBRT, with two immunotherapy drugs, ipilimumab and nivolumab, for advanced kidney cancer. It compares giving SBRT with these drugs versus giving the drugs alone, for patients who can't have surgery.
For: Metastatic Renal Cell CarcinomaAustralia · Canada - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2 BIOmarker driven trial with Nivolumab and Ipilimumab or VEGFR tKi in naïve metastatic Kidney cancer
This study is looking at new drug combinations (Nivolumab and Ipilimumab, or a VEGFR tKi) for kidney cancer that has spread. It aims to see how many people respond to the treatments and how long those responses last, hoping to find better ways to fight the cancer.
For: Kidney cancerFrance